Positive interaction of carmoterol, a new long-acting β2-agonist, with budesonide

R. Razzetti, F. Pastore, M. Civelli, G. Rossoni (Parma, Milan, Italy)

Source: Annual Congress 2005 - New perspectives in asthma treatment
Session: New perspectives in asthma treatment
Session type: Poster Discussion
Number: 1397
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Razzetti, F. Pastore, M. Civelli, G. Rossoni (Parma, Milan, Italy). Positive interaction of carmoterol, a new long-acting β2-agonist, with budesonide. Eur Respir J 2005; 26: Suppl. 49, 1397

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2-adrenoreceptor agonist
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids
Source: Eur Respir J 2002; 19: 182-191
Year: 2002



Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbations
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012

Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014


Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long-acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol
Source: Eur Respir J 2001; 18: Suppl. 33, 156s
Year: 2001

Short-acting beta-agonist (SABA) and airway inflammation: dynamic negative interaction
Source: Eur Respir J 2002; 20: Suppl. 38, 110s
Year: 2002

Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs
Source: Annual Congress 2011 - Understanding disease and drug mechanisms
Year: 2011


Triple combination of montelukast or tiotropium and inhaled corticosteroids plus long-acting ß2-agonist in persistent asthma
Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases
Year: 2018




Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β2 agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone
Source: Eur Respir J 2003; 22: Suppl. 45, 235s
Year: 2003

Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010

Beclomethasone, formoterol and glycopyrronium: synergism of triple therapy on human airways
Source: International Congress 2019 – Advances in COPD pharmacology
Year: 2019

Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients
Source: Annual Congress 2007 - Mechanisms and new treatments of COPD
Year: 2007


Comparison of add-on of leukotriene receptor antagonist vs. long-acting beta2-agonist on FeNO in asthmatic children on regular inhaled budesonide
Source: Eur Respir J 2002; 20: Suppl. 38, 431s
Year: 2002

Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


Emerging inhaled bronchodilators: an update
Source: Eur Respir J 2009; 34: 757
Year: 2009



Comparison of roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, with beclomethasone dipropionate in asthma control
Source: Eur Respir J 2002; 20: Suppl. 38, 304s
Year: 2002